Broker Recommendations

Zantac litigation fears overdone at GSK, says Shore Capital

By Benjamin Chiou

Date: Tuesday 11 Jun 2024

(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.
GSK announced on Tuesday it has started...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page